Patents by Inventor Pallavi Sachdev

Pallavi Sachdev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING AN ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY AND ANTI-TAU ANTIBODY
    Publication number: 20250051427
    Abstract: Disclosed herein are antibodies, pharmaceutical formulations for treating or preventing Alzheimer's disease, methods of treating or preventing Alzheimer's disease, and kits comprising pharmaceutical formulations for treating or preventing Alzheimer's Disease comprising an anti-A? protofibril antibody and anti-tau antibody.
    Type: Application
    Filed: November 8, 2022
    Publication date: February 13, 2025
    Inventors: Larisa REYDERMAN, Jin ZHOU, Lynn KRAMER, Michael IRIZARRY, Pallavi SACHDEV, Shobha DHADDA, David LI, Kristin WILDSMITH, Pau ACEVES BALDO, Sumit RAWAL, Akihiko KOYAMA, Chad SWANSON, Michio KANEKIYO, June KAPLOW, David VERBEL, Ishani LANDRY, Seiichi HAYATO, Robert GORDON, Randall BATEMAN, Eric MCDADE
  • SUBCUTANEOUS FORMULATIONS OF ANTI-ABETA PROTOFIBRIL ANTIBODY AND METHODS OF USE THEREOF
    Publication number: 20240352109
    Abstract: Disclosed herein are methods of treating Alzheimer's disease, methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of reducing brain amyloid level in a subject, methods of converting a subject from amyloid positive to amyloid negative, methods of preventing Alzheimer's disease, the methods comprising subcutaneously administering an anti-A? protofibril antibody.
    Type: Application
    Filed: August 29, 2022
    Publication date: October 24, 2024
    Inventors: Akihiko Koyama, Chad Swanson, Michio KANEKIYO, Michael IRIZARRY, Lynn Kramer, June KAPLOW, David VERBEL, Shobha DHADDA, Pallavi SACHDEV, Larisa REYDERMAN, Ishani Landry, Seiichi HAYATO, Robert Gordon
  • Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
    Patent number: 10517861
    Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: December 31, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Pallavi Sachdev
  • BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS
    Publication number: 20160089366
    Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
    Type: Application
    Filed: May 12, 2014
    Publication date: March 31, 2016
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Pallavi Sachdev